Premarket Buying Signals for Selling to Medical Device Companies

If you sell to medical device companies, your prospect list probably starts with a clearance. A new 510(k) shows up, a rep adds the company to a sequence, and the first call lands a few weeks later. By then the company has usually chosen the contract manufacturer, test lab, quality system, regulatory consultant, and software it needed to get there.

The work that creates demand in medtech happens before the FDA decision. A team is writing design controls, running verification testing, preparing a submission, and hiring its first quality lead months or years before any clearance is public. That premarket stretch is when many of a device company's first vendor decisions are made.

This guide covers how to find those companies while they are still premarket. It ranks the public records that show premarket activity, gives you a weekly checklist for the two most useful ones, and explains how to turn a record into an account decision. The method applies whether you sell services, components, software, or capital equipment into the device industry.

Why a Clearance Record Is a Late Signal

Start with what the FDA record can and cannot tell you. A 510(k) is a premarket submission showing that a device is substantially equivalent to a legally marketed device, and a company must submit it at least 90 days before offering the device for sale ^[1]. Premarket approval is the FDA's scientific and regulatory review process for Class III devices ^[2]. The De Novo request is the pathway for novel devices that have no valid predicate ^[3].

All three pathways end in a public decision, and the work before that decision happens out of public view. openFDA's 510(k) data covers clearance records from 1976 to the present and is updated monthly ^[4]. It is a record of decisions, so a submission still under review is absent from it.

That makes a clearance useful for two things:

• Commercial launch timing. A company with its first clearance can now sell the device, so sales, service, distribution, and post-market processes become likely next projects. If you sell into that phase, the clearance is on time.
• Pipeline inference. A company that cleared one device in a product family often has the next one in development. The clearance tells you the team, the product code, and the regulatory pathway they know.

If what you sell is bought during development, you need records that appear earlier.

The Premarket Signal Map

A device company leaves public traces long before a decision letter. Each trace maps to a development stage and a likely set of purchases. The table ranks them roughly from earliest to latest.

Two points about this map shape how you use every row.

First, the FDA's own confidentiality rules shape what you can see. Before issuing a marketing authorization, the FDA generally cannot publicly disclose whether a sponsor has requested or received Breakthrough Device designation, unless the sponsor chooses to make that public ^[5]. The early signals come from the company itself: its investors, its hiring manager, and its study registrations.

Second, the buying signal is a combination of rows. A Form D filing tells you a company raised money. A Form D filing plus a first regulatory affairs posting plus a registered feasibility study suggests a company is funded, building a quality function, and generating clinical evidence this year. You act on the combination.

Check the Two Best Sources Every Week

Two public sources answer the questions that matter most: which companies are running device studies now, and which have already been cleared. Checking them yourself once teaches your team what the data looks like and where it is thin, which makes everyone a better judge of any vendor list built on it.

Registered device studies on ClinicalTrials.gov. Every registered study lists its sponsor, its recruitment status, and its study start date ^[6]. Each week, look for industry-sponsored device studies that are recruiting or about to recruit, and record:

• The sponsor. This is your account name.
• The study start date. It tells you whether the study is still ahead of the company or already under way.
• The recruitment status. "Not yet recruiting" means enrollment has yet to begin. Use it as a reason to ask whether sites and study tools are already chosen.
• Whether the sponsor already holds clearances in the same product area. Large manufacturers run many post-market studies, so move those sponsors to a separate established-manufacturer list.

Recent 510(k) clearances in your specialty. openFDA's 510(k) records include decision dates and the advisory committee, which identifies the medical specialty ^[4]. Each month, review the clearances decided in your specialty and use the applicant names to split your study sponsors into two lists:

Keep the established manufacturers. A new program can still be a valid opportunity, worked as a different sale with a different buyer.

Turn a Signal Into an Account Decision

A record is an input. The account decision needs three more things: fit, stage, and owner.

Fit. Does this device type need what you sell? Software in a medical device, sterile implants, and reusable capital equipment have different development work and different vendors. Use the product area from the study title, the grant abstract, or a prior clearance's product code to check fit before anything else.

Stage. Place the company on a simple timeline: concept, design and development, verification and validation, submission, launch. Each signal in the table suggests a stage, and two signals narrow it. Write the stage and the evidence link in the account record, so the next rep can see why the stage was chosen.

Owner. Early device companies are small. The person who owns your problem may be the founder, a VP of R&D, a head of quality and regulatory, or a fractional consultant. Titles are inconsistent. Look for who is named on the grant, who posted the role, and who is listed as the study contact.

Then score the account with a rubric your team can argue about in the open:

The point values are an illustrative starting rubric. Change the weights after a quarter of results. What matters is that every score has a link behind it, so that a manager can audit why an account was prioritized.

This is the same discipline described in signal-based prospecting: a signal earns outreach only when it is recent, sourced, and tied to a problem you solve. If medtech is new ground for your team, the approach in entering a new vertical without references covers how to build credibility while the list matures.

Write Outreach Grounded in the Public Record

Premarket teams are cautious about what they disclose, and they notice when a seller overstates what it knows. A study registration leaves out their submission date, and a job posting leaves out the state of their quality system. Write to the evidence and ask about the rest.

A workable structure:

1. 1.Name the public fact. "I saw your feasibility study was registered in June."
2. 2.Connect it to a common problem at that stage. "Teams at that point are often deciding how to handle verification testing capacity."
3. 3.Ask a question they can answer in one line. "Is that in-house for you, or are you still choosing a lab?"

Leave their regulatory pathway, timeline, and FDA interactions for them to describe, and reference only what is public. If the reply is "we settled that last year," record it. That answer corrects your stage estimate and tells you which later purchase to come back for.

Timing the second touch matters as much as the first. When a premarket company says "not yet," take the answer at face value. Set the follow-up to the next expected stage change, such as study completion or a new regulatory hire.

Keep the List Alive

Premarket lists decay in both directions. Companies advance, stall, get acquired, or shut down, and one funding event can change the whole account, so a weekly rhythm fits this segment.

Set up a light weekly routine:

• Check new registered device studies and recent clearances in your specialty, and compare the sponsor names with last week's list.
• Check new Form D filings for the industry and states you cover ^[7].
• Review new quality, regulatory, and clinical job postings at accounts already on the list.
• Move any account with a new clearance from the premarket list to the launch list, with a different message and often a different owner.
• Expire any signal older than twelve months unless a newer one supports it.

This is where tooling helps. Greenway's buying signal view tracks account changes such as funding, hiring, and company announcements, and the researched leads workflow attaches the source and the likely owner to each account so a rep starts from evidence. Industry-specific registries like the ones above are worth checking directly as well. Your team still decides which combinations of signals count as a stage change for what you sell.

Frequently Asked Questions

Can I see 510(k) submissions that are still under review?

The public 510(k) data is a record of clearance decisions ^[4], so submissions under review stay out of view. To find companies before a decision, use the earlier traces: funding filings, hiring, grants, and registered studies.

Is a Breakthrough Device designation a reliable early signal?

Only when the company announces it. The FDA generally cannot disclose a designation request or decision before marketing authorization unless the sponsor makes it public ^[5]. When a sponsor does announce one, it confirms active FDA interaction and a device aimed at a serious condition.

How far ahead of clearance do these signals appear?

It varies too much by device type and pathway to give one number. A software device on a 510(k) path and an implant on a PMA path run on very different timelines. Track the interval in your own closed deals: the date of the first signal you could have seen against the date the company bought.

What if the account is a large manufacturer and not a startup?

The same records apply, and the signal points somewhere narrower. A new study from an established manufacturer points to a specific program and business unit. Route it to the rep who owns that account and look for the program lead.

Should we buy a medtech intent data feed?

Check what it is built from first. If the feed is mostly clearance records and web traffic, you can reproduce the useful part yourself, and it will still point you at companies after their decision. A feed earns its cost when it combines several early records, dates each one, and links to the source.

Start with One Specialty and Fifty Names

Pick the one device specialty where you already have customers. Pull the registered device studies for it, move sponsors with prior clearances in that specialty to a separate established-manufacturer list, and add funding and hiring evidence for whoever remains. Fifty sourced names with a stage and an owner are a better place to spend a rep's week than a long list of cleared companies, because you have evidence that each of the fifty may still be deciding.

Review the list weekly for a quarter, record which signals preceded real conversations, and adjust the rubric. Use what you learn to decide which records deserve a weekly check and which data sources are worth paying for.

References

[1] U.S. Food and Drug Administration, Premarket Notification 510(k). https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-notification-510k

[2] U.S. Food and Drug Administration, Premarket Approval (PMA). https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-approval-pma

[3] U.S. Food and Drug Administration, De Novo Classification Request. https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/de-novo-classification-request

[4] openFDA, Device 510(k) API. https://open.fda.gov/apis/device/510k/

[5] U.S. Food and Drug Administration, Breakthrough Devices Program. https://www.fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program

[6] ClinicalTrials.gov, API Documentation. https://clinicaltrials.gov/data-api/api

[7] U.S. Securities and Exchange Commission, Form D. https://www.sec.gov/resources-small-businesses/capital-raising-building-blocks/form-d

[8] National Institutes of Health, NIH RePORTER. https://reporter.nih.gov/